Compare MDAI & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDAI | DARE |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | 65 | 24 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 35.5M |
| IPO Year | N/A | 2014 |
| Metric | MDAI | DARE |
|---|---|---|
| Price | $2.70 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | 544.1K | ★ 769.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $2,115.12 |
| Revenue Next Year | $23.50 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $1.27 |
| 52 Week High | $3.21 | $9.19 |
| Indicator | MDAI | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 70.51 | 48.90 |
| Support Level | $1.39 | $1.79 |
| Resistance Level | $2.80 | $2.54 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 94.02 | 22.28 |
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.